Form 8-K - Current report:
SEC Accession No. 0001193125-25-024838
Filing Date
2025-02-12
Accepted
2025-02-12 08:52:21
Documents
21
Period of Report
2025-02-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d901857d8k.htm   iXBRL 8-K 42327
2 EX-4.1 d901857dex41.htm EX-4.1 74247
3 EX-4.2 d901857dex42.htm EX-4.2 85364
4 EX-10.1 d901857dex101.htm EX-10.1 260517
5 EX-10.2 d901857dex102.htm EX-10.2 129154
6 EX-10.3 d901857dex103.htm EX-10.3 76146
7 EX-10.4 d901857dex104.htm EX-10.4 20947
8 EX-99.1 d901857dex991.htm EX-99.1 10428
12 GRAPHIC g901857dsp50.jpg GRAPHIC 3903
  Complete submission text file 0001193125-25-024838.txt   1006779

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA algs-20250211.xsd EX-101.SCH 2877
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20250211_lab.xml EX-101.LAB 18737
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20250211_pre.xml EX-101.PRE 11725
23 EXTRACTED XBRL INSTANCE DOCUMENT d901857d8k_htm.xml XML 3780
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 25612197
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)